{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:13:44Z","timestamp":1792613624544,"version":"4.5.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Using population-based data from Sweden, we identified all multiple myeloma (MM) patients (n = 8740) and 5652 monoclonal gammopathy of undetermined significance (MGUS) patients diagnosed between 1986 and 2005. We calculated standardized incidence rates (SIRs) for all subsequent hematologic and nonhematologic malignancies for MM patients diagnosed before\/after 1995 (introduction of high-dose melphalan\/autologous stem cell transplantation [HDM-ASCT]) and 2000 (introduction of immunomodulatory drugs [IMiDs]), respectively. MM patients had an 11.51-fold (95% confidence interval: 8.19-15.74) increased risk of acute myeloid leukemia (AML)\/myelodysplastic syndromes (MDS); risk was very similar before\/after 1995 and 2000, respectively. MGUS patients had an 8.01-fold (5.40-11.43) increased risk of AML\/MDS. Risk was confined to IgG\/IgA, while no IgM MGUS patients developed AML\/MDS; patients with monoclonal-protein (M-protein) concentrations &amp;gt; 1.5 g\/dL (SIR = 11.12; 3.61-25.96) had higher risk than those &amp;lt; 1.5 g\/dL (SIR = 4.67; 1.71-10.16). An excess risk of nonmelanoma skin cancer was observed subsequent to both MM (SIR = 2.22; 1.74-2.80) and MGUS (SIR = 3.30; 2.76-3.90). Our novel observations of an excess risk for AML\/MDS following IgG\/IgA (but not IgM) MGUS, and the highest risk associated with M-protein concentrations &amp;gt; 1.5 g\/dL, support a role for nontreatment-related factors in plasma cell dyscrasias. AML\/MDS risk following MM was the same before\/after the introduction of HDM-ASCT. Longer follow-up is needed to characterize second tumor risks in the IMiD era.<\/jats:p>","DOI":"10.1182\/blood-2011-05-355743","type":"journal-article","created":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T04:35:55Z","timestamp":1311827755000},"page":"4086-4092","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":177,"title":["Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)"],"prefix":"10.1182","volume":"118","author":[{"given":"Sham","family":"Mailankody","sequence":"first","affiliation":[{"name":"Multiple Myeloma Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"},{"name":"Washington Hospital Center, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth M.","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurdur Y.","family":"Kristinsson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology Center, Karolinska University Hospital and Institutet, Stockholm, Sweden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Korde","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Bjorkholm","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology Center, Karolinska University Hospital and Institutet, Stockholm, Sweden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn R.","family":"Goldin","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingemar","family":"Turesson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology Section, Skane University Hospital, Malmo, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2020071612103608300_B1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010.","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"2020071612103608300_B2","first-page":"1","article-title":"The survival time of patients with plasmocytic myeloma.","volume":"9","author":"Osgood","year":"1960","journal-title":"Cancer Chemother Rep"},{"issue":"4","key":"2020071612103608300_B3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0277-5379(83)90113-X","article-title":"Intermittent high-dose melphalan\/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.","volume":"19","author":"Ahre","year":"1983","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"2","key":"2020071612103608300_B4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome.","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"2020071612103608300_B5","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"2020071612103608300_B6","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"issue":"10","key":"2020071612103608300_B7","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2020071612103608300_B8","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"issue":"36","key":"2020071612103608300_B9","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020071612103608300_B10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020071612103608300_B11","first-page":"7","article-title":"Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.","volume":"95","author":"Lenhoff","year":"2000","journal-title":"Blood"},{"issue":"21","key":"2020071612103608300_B12","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma.","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"issue":"26","key":"2020071612103608300_B13","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"2020071612103608300_B14","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"2020071612103608300_B15","first-page":"3","article-title":"Multiple myeloma I. The pathogenesis of amyloidosis.","volume":"1","author":"Osserman","year":"1964","journal-title":"Semin Hematol"},{"issue":"21","key":"2020071612103608300_B16","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJM197011192832101","article-title":"Multiple myeloma and acute myelomonocytic leukemia.","volume":"283","author":"Kyle","year":"1970","journal-title":"N Engl J Med"},{"issue":"7","key":"2020071612103608300_B17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1054\/bjoc.2001.1998","article-title":"Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958\u20131996: a search for common mechanisms.","volume":"85","author":"Dong","year":"2001","journal-title":"Br J Cancer"},{"key":"2020071612103608300_B18","volume-title":"New Malignancies among Cancer Survivors: SEER Cancer Registries, 1973\u20132000","author":"Curtis","year":"2006"},{"issue":"5","key":"2020071612103608300_B19","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.1987.107","article-title":"A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults.","volume":"55","author":"Cuzick","year":"1987","journal-title":"Br J Cancer"},{"issue":"14","key":"2020071612103608300_B20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJM197910043011402","article-title":"The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia.","volume":"301","author":"Bergsagel","year":"1979","journal-title":"N Engl J Med"},{"issue":"2","key":"2020071612103608300_B21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2141.1996.d01-1891.x","article-title":"Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma.","volume":"95","author":"Govindarajan","year":"1996","journal-title":"Br J Haematol"},{"issue":"2","key":"2020071612103608300_B22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1034\/j.1600-0609.2000.90218.x","article-title":"Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study.","volume":"65","year":"2000","journal-title":"Eur J Haematol"},{"issue":"2","key":"2020071612103608300_B23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/10428194.2010.529207","article-title":"Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma.","volume":"52","author":"Hasskarl","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"2020071612103608300_B24","article-title":"Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02 [abstract].","volume":"116","author":"Attal","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"2020071612103608300_B25","article-title":"A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients \u2265 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens [abstract].","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"2020071612103608300_B26","article-title":"Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract].","volume":"116","author":"McCarthy","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"4","key":"2020071612103608300_B27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2141.2005.05867.x","article-title":"Guidelines on the diagnosis and management of multiple myeloma 2005.","volume":"132","author":"Smith","year":"2006","journal-title":"Br J Haematol"},{"issue":"5","key":"2020071612103608300_B28","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.","volume":"28","author":"Turesson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020071612103608300_B29","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/ijc.22912","article-title":"Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964\u20132003.","volume":"121","author":"Turesson","year":"2007","journal-title":"Int J Cancer"},{"key":"2020071612103608300_B30","volume-title":"Cancer Incidence in Sweden 2006","year":"2007"},{"issue":"15","key":"2020071612103608300_B31","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020071612103608300_B32","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3324\/haematol.2009.010066","article-title":"Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study.","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"2020071612103608300_B33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.0954-6820.1966.tb05453.x","article-title":"Frequency of pathological proteins (M-components) om 6,995 sera from an adult population.","volume":"179","author":"Axelsson","year":"1966","journal-title":"Acta Med Scand"},{"issue":"5","key":"2020071612103608300_B34","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"issue":"6","key":"2020071612103608300_B35","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"2020071612103608300_B36","volume-title":"Patientregistret 1987\u20131996: Kvalitet Och Inneh\u00e5ll (Swedish)","author":"Anonymous","year":"1998"},{"issue":"8","key":"2020071612103608300_B37","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance.","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"22","key":"2020071612103608300_B38","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2020071612103608300_B39","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients.","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2020071612103608300_B40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00320010","article-title":"Frequent association of idiopathic myelofibrosis with plasma cell dyscrasias.","volume":"56","author":"Duhrsen","year":"1988","journal-title":"Blut"},{"issue":"13","key":"2020071612103608300_B41","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/15\/4086\/1341596\/zh804111004086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/15\/4086\/1341596\/zh804111004086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T19:23:05Z","timestamp":1594927385000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/15\/4086\/29008\/Risk-of-acute-myeloid-leukemia-and-myelodysplastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,13]]},"references-count":41,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2011,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-05-355743","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,13]]}}}